Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Kala Pharmaceuticals Inc (KALA)

Kala Pharmaceuticals Inc (KALA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Kala Pharmaceuticals Inc 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 USA

P: 781-996-5252 F: 781-642-0399

Description:

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States.

Key Statistics

Overview:

Market Capitalization, $K 24,399
Enterprise Value, $K 24,422
Shares Outstanding, K 72,594
Annual Sales, $ 11,240 K
Annual Net Income, $ -142,610 K
Last Quarter Sales, $ 1,370 K
Last Quarter Net Income, $ -32,940 K
60-Month Beta 1.04
% of Insider Shareholders 20.04%
% of Institutional Shareholders 52.81%
Float, K 58,046
% Float 79.96%
Short Volume Ratio 0.47

Growth:

1-Year Return -88.91%
3-Year Return -91.60%
5-Year Return -98.43%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.45 on 05/16/22
Next Earnings Date 08/11/22
Earnings Per Share ttm -2.13
EPS Growth vs. Prev Qtr 15.56%
EPS Growth vs. Prev Year 33.33%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

KALA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -562.06%
Return-on-Assets % -92.23%
Profit Margin % -1,268.77
Net Margin % N/A
Debt/Equity N/A
Price/Sales 2.12
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.07
Interest Coverage -16.02
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar